Drug Trial Radar · NCT06586294
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Sep 30, 2024
Primary completion
Apr 20, 2026
Study completion Apr 20, 2026
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase Ib/II clinical study of AK129 combined with chemotherapy with or without cadonilimab in first-line treatment of advanced HER2 negative gastric cancer or gastroesophageal junction adenocarcinoma
Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
Interventions
Drug: AK129 Drug:oxaliplatin Drug:capecitabineDrug
The study drug will be administered at the specified dose and frequency.
Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabineDrug
The study drug will be administered at the specified dose and frequency.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events(AE)Time frame: Up to approximately 2 years
- Incidence of serious adverse events(SAE) and suspected unexpected serious adverse reactions(SUSAR)Time frame: Up to approximately 2 years
- Incidence of dose-limiting toxicity(DLT)Time frame: Up to approximately 2 years
- Clinically significant changes in safety/laboratory evaluation parameters and AEs that led to treatment termination or suspensionTime frame: Up to approximately 2 years
- Objective Solution Rate (ORR) based on RECIST v1.1Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Cancer Hospital
Hanzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.